Similarly, Zhao et al. (2024) elucidated a gefitinib resistance mechanism in non-small cell lung cancer (NSCLC) driven by S6K1 hyperactivation, a process mediated through the ELK1/mTOR/S6K1 signaling axis. This evidence concerns the gene ELK1 and non-small cell lung carcinoma.